ProCE Banner Activity

Danish COMBI Trial: Addition of Ruxolitinib to Interferon-α2 Therapy in Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Slideset Download
Conference Coverage
Ruxolitinib addition to IFN-α2 showed early activity with a manageable toxicity profile in tx-experienced MPN.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen